BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report
Susanna Gallo(Candiolo Cancer Institute), Fabrizio Carnevale‐Schianca(Candiolo Cancer Institute), Alessandro Zaccagna(University Dermatology), Massimo Aglietta(Verizon (United States)), Manuela Racca(Fondazione Piemontese per la Ricerca sul Cancro Onlus), Valentina Coha, Loretta Gammaitoni, Alberto Pisacane, Elena Giacone(University Dermatology), Federica Marenco(University Dermatology), Daniela Caravelli(Candiolo Cancer Institute), Paolo Becco(University of Turin), Tiziana Venesio(Candiolo Cancer Institute)
Cited by 5
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|264